Ibrutinib Solid Dispersion Formulations for Pharmacokinetic Variability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with Bruton's tyrosine kinase (Btk) activity, such as autoimmune diseases and cancers, face challenges in achieving optimal pharmacokinetic properties and reduced variability in drug exposure.
Innovation Solution
Development of solid dispersion pharmaceutical compositions, specifically spray-dried ibrutinib formulations, which include ibrutinib dispersed in a polymer matrix, providing improved pharmacokinetic properties and reduced variability compared to traditional capsule formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional capsule formulations are used, then manufacturing simplicity is maintained, but pharmacokinetic properties and drug exposure are insufficient
Solution Approach 1:
The patent changes the physical state parameter of ibrutinib from crystalline to amorphous form, and incorporates it into a polymer matrix system. This parameter change transforms the formulation from a simple capsule to a solid dispersion system, thereby improving pharmacokinetic properties including drug exposure and reduced variability while maintaining manufacturing feasibility through established spray drying and encapsulation techniques
Solution Approach 2:
The patent creates a composite formulation by combining ibrutinib with polymer matrices (such as HPMC, PVP, or Eudragit). This composite approach embeds the drug within the polymer structure, forming a solid dispersion that enhances drug solubility, dissolution rate, and bioavailability, thus improving pharmacokinetic reliability without requiring complex manufacturing processes
2Reliability
If high drug exposure is achieved, then therapeutic efficacy is improved, but variability in drug exposure increases
Solution Approach 1:
The patent utilizes the amorphous state of ibrutinib within the polymer matrix, which creates a more uniform and predictable dissolution profile compared to crystalline forms. This parameter change in molecular arrangement reduces variability in drug release and absorption, leading to more consistent drug exposure across different patients and dosing conditions
Solution Approach 2:
The solid dispersion formulation ensures homogeneous distribution of ibrutinib molecules within the polymer matrix at the molecular level. This homogeneity eliminates the variability associated with crystalline particle size and aggregation, resulting in consistent dissolution behavior and predictable pharmacokinetic profiles across the patient population
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion formulations of ibrutinib offer enhanced drug exposure and reduced variability in pharmacokinetic parameters, leading to improved therapeutic efficacy in treating Btk-associated diseases.
Implementation Method 1
spray-dried ibrutinib formulations, which include ibrutinib dispersed in a polymer matrix
Implementation Method 2
solid dispersed ibrutinib is spray-dried ibrutinib
Data Source
AI summary
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.